Syros Pharmaceuticals (NASDAQ:SYRS) Stock Passes Below 50-Day Moving Average of $6.38

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) shares passed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $6.38 and traded as low as $5.18. Syros Pharmaceuticals shares last traded at $5.56, with a volume of 287,306 shares traded.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on SYRS. Piper Sandler restated an “overweight” rating and set a $13.00 target price on shares of Syros Pharmaceuticals in a report on Wednesday, April 3rd. StockNews.com cut Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, April 5th. Finally, HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Syros Pharmaceuticals in a report on Monday, April 1st.

Syros Pharmaceuticals Price Performance

The company has a current ratio of 3.95, a quick ratio of 3.95 and a debt-to-equity ratio of 2.07. The firm has a market cap of $147.06 million, a P/E ratio of -0.97 and a beta of 1.75. The company has a fifty day moving average price of $6.38 and a two-hundred day moving average price of $5.19.

Hedge Funds Weigh In On Syros Pharmaceuticals

Several institutional investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in shares of Syros Pharmaceuticals by 44.8% during the 4th quarter. Vanguard Group Inc. now owns 764,812 shares of the company’s stock valued at $5,958,000 after purchasing an additional 236,620 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Syros Pharmaceuticals by 125.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 239,681 shares of the company’s stock valued at $1,867,000 after purchasing an additional 133,149 shares in the last quarter. Blue Owl Capital Holdings LP bought a new position in shares of Syros Pharmaceuticals during the 4th quarter valued at about $11,632,000. Opaleye Management Inc. bought a new position in shares of Syros Pharmaceuticals during the 4th quarter valued at about $2,799,000. Finally, Flagship Pioneering Inc. lifted its holdings in shares of Syros Pharmaceuticals by 30.2% during the 4th quarter. Flagship Pioneering Inc. now owns 1,293,848 shares of the company’s stock valued at $10,079,000 after purchasing an additional 300,000 shares in the last quarter. Institutional investors own 91.47% of the company’s stock.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.